RHOA mutation in follicular T-cell lymphoma: Clinicopathological analysis of 16 cases.
RHOA mutation
follicular T-cell lymphoma
immunohistochemistry
malignant lymphoma
mutation
pathology
Journal
Pathology international
ISSN: 1440-1827
Titre abrégé: Pathol Int
Pays: Australia
ID NLM: 9431380
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
24
03
2020
revised:
04
06
2020
accepted:
16
06
2020
pubmed:
11
7
2020
medline:
23
6
2021
entrez:
11
7
2020
Statut:
ppublish
Résumé
Follicular T-cell lymphoma (FTCL) is considered to originate from follicular helper T-cell (Tfh) cells. Angioimmunoblastic T-cell lymphoma (AITL) and peripheral T-cell lymphomas with the Tfh phenotype, derived from Tfh cells, often harbor RHOA G17V mutation. We investigated whether RHOA mutations affect the clinicopathological features of FTCL. We performed deep sequencing and Sanger sequencing for RHOA exon 2 in 16 cases of FTCL. Nine cases showed RHOA mutations, including eight with c.G50T, p.Gly17Val and one with c.G50A, p.Gly17Glu, c.A52G, p.Lys18Glu, c.T102C, p.Tyr34Tyr and c.G145T, p.Asp49Tyr. Compared to the RHOA mutation-negative group, the RHOA mutation-positive group had a higher tendency for B-immunoblasts (P = 0.06), the AITL component (P = 0.09), and higher positive rate for CD10 (P = 0.09) and BCL6 (P = 0.09), and a significantly higher positive rate for CXCL13 (P = 0.04). Although not statistically significant, the RHOA mutation-positive group showed higher values for almost all characteristic AITL features. There was no significant difference in overall survival between RHOA mutation-positive and -negative groups. The RHOA mutation may play an important role in clinicopathological characteristics and lymphomagenesis of FTCL. A more detailed investigation is needed to highlight the importance of RHOA mutations in FTCL.
Substances chimiques
Biomarkers, Tumor
0
RHOA protein, human
124671-05-2
rhoA GTP-Binding Protein
EC 3.6.5.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
653-660Informations de copyright
© 2020 Japanese Society of Pathology and John Wiley & Sons Australia, Ltd.
Références
Dogan A, Gaulard P, Jaffe ES et al. Angioimmunoblastic T-cell lymphoma and other nodal lymphomas of T-follicular helper cell origin. In: Swerdlow SH, Campo E, Harris NL et al., eds. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues, Revised, 4th edn. Lyon, France: IARC Press, 2017; 407-12.
Miyoshi H, Sato K, Niino D et al. Clinicopathologic analysis of peripheral T-cell lymphoma, follicular variant, and comparison with angioimmunoblastic T-cell lymphoma: Bcl-6 expression might affect progression between these disorders. Am J Clin Pathol 2012; 137: 879-89.
Agostinelli C, Hartmann S, Klapper W et al. Peripheral T cell lymphomas with follicular T helper phenotype: A new basket or a distinct entity? Revising Karl Lennert's personal archive. Histopathology 2011; 59: 679-91.
Bacon CM, Paterson JC, Liu H et al. Peripheral T-cell lymphoma with a follicular growth pattern: Derivation from follicular helper T cells and relationship to angioimmunoblastic T-cell lymphoma. Br J Haematol 2008; 143: 439-41.
de Leval L, Savilo E, Longtine J et al. Peripheral T-cell lymphoma with follicular involvement and a CD4+/bcl-6+ phenotype. Am J Surg Pathol 2001; 25: 395-400.
Huang Y, Moreau A, Dupuis J et al. Peripheral T-cell lymphomas with a follicular growth pattern are derived from follicular helper T cells (TFH) and may show overlapping features with angioimmunoblastic T-cell lymphomas. Am J Surg Pathol 2009; 33: 682-90.
Sakata-Yanagimoto M, Enami T, Yoshida K et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet 2014; 46: 171-75.
Palomero T, Couronné L, Khiabanian H et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet 2014; 46: 166-70.
Yoo HY, Sung MK, Lee SH et al. A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. Nat Genet 2014; 46: 371-75.
Kakiuchi M, Nishizawa T, Ueda H et al. Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. Nat Genet 2014; 46: 583-87.
Rohde M, Richter J, Schlesner M et al. Recurrent RHOA mutations in pediatric Burkitt lymphoma treated according to the NHL-BFM protocols. Genes Chromosomes Cancer 2014; 53: 911-16.
Fujisawa M, Sakata-Yanagimoto M, Nishizawa S et al. Activation of RHOA-VAV1 signaling in angioimmunoblastic T-cell lymphoma. Leukemia 2018; 32: 694-702.
Abate F, da Silva-Almeida AC, Zairis S et al. Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas. Proc Natl Acad Sci USA 2017; 114: 764-69.
Shenoy N, Bhagat T, Nieves E et al. Upregulation of TET activity with ascorbic acid induces epigenetic modulation of lymphoma cells. Blood Cancer J 2017; 7: e587.
Vallois D, Dobay MP, Morin RD et al. Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas. Blood 2016; 128: 1490-502.
Yoo HY, Kim P, Kim WS et al. Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma. Haematologica 2016; 101: 757-63.
Dobay MP, Lemonnier F, Missiaglia E et al. Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin. Haematologica 2017; 102: e148-51.
Shimono J, Miyoshi H, Kiyasu J et al. Clinicopathological analysis of polyploid diffuse large B-cell lymphoma. PLoS One 2018; 13: e0194525.
Nagao R, Kikuti YY, Carreras J et al. Clinicopathologic analysis of angioimmunoblastic T-cell lymphoma with or without RHOA G17V mutation using formalin-fixed paraffin-embedded sections. Am J Surg Pathol 2016; 40: 1041-50.
Ondrejka SL, Grzywacz B, Bodo J et al. Angioimmunoblastic T-cell lymphomas with the RHOA p.Gly17Val mutation have classic clinical and pathologic features. Am J Surg Pathol 2016; 40: 335-41.
Cortes JR, Ambesi-Impiombato A, Couronné L et al. RHOA G17V induces T follicular helper cell specification and promotes lymphomagenesis. Cancer Cell 2018; 33: 259-73.
Ng SY, Brown L, Stevenson K et al. RhoA G17V is sufficient to induce autoimmunity and promotes T cell lymphomagenesis in mice. Blood 2018; 132: 935-47.